Found: 12
Select item for more details and to access through your institution.
Potential Role of Tamoxifen in Prevention of Breast Cancer.
- Published in:
- JNCI: Journal of the National Cancer Institute, 1991, v. 83, n. 20, p. 1450, doi. 10.1093/jnci/83.20.1450
- By:
- Publication type:
- Article
BOOK REVIEWS.
- Published in:
- JNCI: Journal of the National Cancer Institute, 1991, v. 83, n. 14, p. 1029, doi. 10.1093/jnci/83.14.1029
- By:
- Publication type:
- Article
BOOK REVIEWS.
- Published in:
- JNCI: Journal of the National Cancer Institute, 1988, v. 80, n. 16, p. 1338
- By:
- Publication type:
- Article
Prognostic factors observed in current clinical trials.
- Published in:
- 1993
- By:
- Publication type:
- journal article
Controversies in the treatment of metastatic prostate cancer.
- Published in:
- Cancer (0008543X), 1992, v. 70, n. S1, p. 324, doi. 10.1002/1097-0142(19920701)70:1+<324::AID-CNCR2820701321>3.0.CO;2-G
- By:
- Publication type:
- Article
Opportunities in clinical trials adjuvant breast cancer.
- Published in:
- Cancer (0008543X), 1990, v. 66, n. S14, p. 1412, doi. 10.1002/1097-0142(19900915)66:14+<1412::AID-CNCR2820661417>3.0.CO;2-S
- By:
- Publication type:
- Article
A phase I trial of aprinocarsen (ISIS 3521/LY900003), an antisense inhibitor of protein kinase C-α administered as a 24-hour weekly infusion schedule in patients with advanced cancer.
- Published in:
- Investigational New Drugs, 2005, v. 23, n. 5, p. 467, doi. 10.1007/s10637-005-2906-0
- By:
- Publication type:
- Article
Efficacy and toxicity of the antisense oligonucleotide aprinocarsen directed against protein kinase C-α delivered as a 21-day continuous intravenous infusion in patients with recurrent high-grade astrocytomas.
- Published in:
- Neuro-Oncology, 2005, v. 7, n. 1, p. 32, doi. 10.1215/S1152851703000353
- By:
- Publication type:
- Article
A Phase II trial of aprinocarsen, an antisense oligonucleotide inhibitor of protein kinase C α, administered as a 21-day infusion to patients with advanced ovarian carcinoma.
- Published in:
- Cancer (0008543X), 2004, v. 100, n. 2, p. 321
- By:
- Publication type:
- Article
A Phase I trial of H-ras antisense oligonucleotide ISIS 2503 administered as a continuous intravenous infusion in patients with advanced carcinoma.
- Published in:
- 2001
- By:
- Publication type:
- journal article
P-225: A first-in-human study of FOR46 in patients with triple refractory Multiple Myeloma.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S164, doi. 10.1016/S2152-2650(21)02352-1
- By:
- Publication type:
- Article
Pharmacokinetic analysis of irinotecan plus bevacizumab in patients with advanced solid tumors.
- Published in:
- Cancer Chemotherapy & Pharmacology, 2009, v. 65, n. 1, p. 97, doi. 10.1007/s00280-009-1008-7
- By:
- Publication type:
- Article